Scrip Podcasts

This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions.

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.  Story links: https://insights.citeli...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 强生上调业绩预期；吉利德的收购策略；拜耳拆分传闻；百健的阿尔茨海默病研究结果；以及对礼来血液检测先驱的专访。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development.

Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/sc...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-thi...

As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global devel...

Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.